ACADIA Pharmaceuticals Inc ACAD:NASDAQ

Last Price$19.19Cboe Real-Time Last Sale as of 1:23PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.01(0.05%)
Bid (Size)$19.16 (100)
Ask (Size)$19.23 (200)
Day Low / High$19.01 - 19.98
Volume370.3 K

View Biotechnology IndustryPeer Comparison as of 12/01/2021


ACADIA Pharmaceuticals Inc ( NASDAQ )

Price: $19.19
Change: -0.01 (0.05%)
Volume: 370.3 K
1:23PM ET 12/01/2021

Arcus Biosciences Inc ( NYSE )

Price: $44.42
Change: +0.62 (1.42%)
Volume: 257.8 K
1:23PM ET 12/01/2021

Immunitybio Inc ( NASDAQ )

Price: $6.84
Change: -0.95 (12.20%)
Volume: 1.5 M
1:22PM ET 12/01/2021

Amicus Therapeutics Inc ( NASDAQ )

Price: $11.18
Change: +0.47 (4.39%)
Volume: 766.7 K
1:22PM ET 12/01/2021

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $38.15
Change: +0.14 (0.37%)
Volume: 2.1 M
1:23PM ET 12/01/2021

Read more news Recent News

--Citigroup Adjusts ACADIA Pharmaceuticals' Price Target to $25 From $22, Maintains Neutral Rating
7:53AM ET 11/09/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

ACADIA Pharmaceuticals Narrows Q3 Net Loss, 2021 Sales Guidance
5:03PM ET 11/08/2021 MT Newswires

ACADIA Pharmaceuticals (ACAD) late Monday reported a Q3 net loss of $0.09 per share, compared with a net loss of $0.54 per share in Q3 2020. Analysts...

-- Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q3 Loss $-0.09, vs. Street Est of $-0.26
4:11PM ET 11/08/2021 MT Newswires


-- Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q3 Revenue $131.6M, vs. Street Est of $127.8M
4:11PM ET 11/08/2021 MT Newswires


Company Profile

Business DescriptionACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. View company web site for more details
Address12830 El Camino Real
San Diego, California 92130-3331
Number of Employees430
Recent SEC Filing11/23/20214
Chief Executive Officer & DirectorStephen R. Davis
PresidentSrdjan R. Stankovic
Chief Operating Officer, EVP & Head-CommercialBrendan P. Teehan
Chief Financial & Business OfficerMark Schneyer

Company Highlights

Price Open$19.01
Previous Close$19.20
52 Week Range$15.68 - 57.34
Market Capitalization$3.1 B
Shares Outstanding160.8 M
SectorHealth Technology
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.97
Beta vs. S&P 500N/A
Revenue$223.8 M
Net Profit Margin-40.37%
Return on Equity-32.74%

Analyst Ratings as of 10/29/2021

Consensus RecommendationConsensus Icon
Powered by Factset